CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

HEPATITIS C PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on
Hepatitis C
Literature Review, December 2014

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial. Buti M1, Flisiak R, Kao JH, et al. J Viral Hepat. 2014 Nov 21. doi: 10.1111/jvh.12360. [Epub ahead of print]

Weight Loss during Telaprevir-based Triple Therapy due to Telaprevir-induced Appetite Loss. Nomura H1, Miyagi Y, Tanimoto H, Kawano A, Yamashita N. Intern Med. 2014;53(22):2567-73. Epub 2014 Nov 15.

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir. Johnson M1, Borland J, Chen S, Savina P, Wynne B, Piscitelli S. Br J Clin Pharmacol. 2014 Nov;78(5):1043-9. doi: 10.1111/bcp.12428.

Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. Gidwani R1, Barnett PG, Goldhaber-Fiebert JD, et al. J Viral Hepat. 2014 Nov 24. doi: 10.1111/jvh.12344. [Epub ahead of print]

Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse: An Open-Label Pilot Study. Osinusi A, Kohli A, Marti MM, et al. Ann Intern Med. 2014 Nov 4;161(9):634-8. doi: 10.7326/M14-1211.

Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study. Poordad F1, Agarwal K2, Younes Z3, Cohen D4, Xie W4,

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. Manns MP1, Fried MW, Zeuzem S, et al. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print]

Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Hsu YC1, Ho HJ2, Huang YT3, Wang HH4, Wu MS5, Lin JT6, Wu CY7. Gut. 2014 Nov 14. pii: gutjnl-2014-308163. doi: 10.1136/gutjnl-2014-308163. [Epub

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies. Lendvai G, Jármay K, Karácsony G, et al. World J Gastroenterol. 2014 Nov 7;20(41):15343-50. doi: 10.3748/wjg.v20.i41.15343.

Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody. Ji C1, Liu Y, Pamulapati C, Bohini S, et al. Hepatology. 2014 Nov 22. doi: 10.1002/hep.27603. [Epub ahead of print]

Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection. Farnik H1, Ferreirós N, Labocha S, et al. Scand J Gas-troenterol. 2014 Dec;49(12):1473-9. doi: 10.3109/00365521.2014.978363. Epub 2014 Nov 11.

HIV/HCV COINFECTION

Hepatitis C virus long-term persistence in peripheral blood mononuclear cells in patients with haemophilia. Detection of occult genotype 1. Parodi C1, García G, Monzani MC, et al. J Viral Hepat. 2014 Nov 27. doi: 10.1111/jvh.12363. [Epub ahead of print]

HCV triple therapy in co-infection HIV/HCV is not associated with a different risk of developing major depressive disorder. Fialho R1, Keller M2, File A2, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19629. doi: 10.7448/IAS.17.4.19629. eCollection 2014.

Monitoring renal function during combination therapy with telaprevir in HIV/HCV co-infected patients with advanced/fibrosis cirrhosis. Puzzolante C, Vecchia M, Zona S, Borghi V, Guaraldi G, Mussini C. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19627. doi: 10.7448/IAS.17.4.19627. eCollection 2014.

Comparison of the Prognostic Value of Liver Biopsy and FIB-4 in Patients Coinfected with the Human Immunodeficiency Virus and Hepatitis C Virus. Berenguer J, Zamora FX, Aldámiz-Echevarría T, et al. Clin Infect Dis. 2014 Nov 24. pii: ciu939. [Epub ahead of print]

Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection. Patel N1, Nasiri M, Koroglu A, Amin R, McGuey L, McNutt LA, Roman M, Miller CD. AIDS Res Hum Retroviruses. 2014 Nov 28. [Epub ahead of print]

Experience of acute hepatitis C and HIV co-infection in an inner city clinic in the UK. Ward C, Lee V. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19639. doi: 10.7448/IAS.17.4.19639. eCollection 2014.

Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. Antonini TM1, Furlan V, Teicher E, et al. AIDS. 2014 Nov 9. [Epub ahead of print]

Analysis of hepatitis non-treatment causes in a cohort of HCV and HCV/HIV infected patients. Pereira K, Miranda AC, Baptista T, Peres S, Antunes I, Ventura F, Borges F, Mansinho K. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19645. doi: 10.7448/IAS.17.4.19645. eCollection 2014.

Effect of HIV infection-related factors on SVR rate in HCV treatment in HIV-infected patients. Kravchenko A, Kuimova U. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19635. doi: 10.7448/IAS.17.4.19635. eCollection 2014.

Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence. Gonzalez-Colominas E1, Broquetas T,et al. Liver Int. 2014 Nov 10. doi: 10.1111/liv.12729. [Epub ahead of print]

Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients. Labarga P1, Fernandez-Montero JV, de Mendoza C, Barreiro P, Pinilla J, Soriano V. Antivir Ther. 2014 Nov 5. doi: 10.3851/IMP2909. [Epub ahead of print]

Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients. Long L, Shen T, Gao J, Duan Z, Liang H, Lu F. BMC Infect Dis. 2014 Nov 5;14:577. doi: 10.1186/s12879-014-0577-1.

FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients. Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, et al. BMC Med. 2014 Nov 3;12(1):198. doi: 10.1186/s12916-014-0198-y.

COMPLEMENTARY AND ALTERNATIVE MEDICINE

The importance of fatigue cognitions in chronic hepatitis C infection. Zalai D1, Sherman M2, McShane K3, Shapiro CM4, Carney CE3. J Psychosom Res. 2014 Nov 18. pii: S0022-3999(14)00391-2. doi: 10.1016/j.jpsychores.2014.11.011. [Epub ahead of print]

 

EPIDEMIOLOGY, DIAGNOSTICS, AND MISCELLANEOUS WORKS

Diagnostic tests for hepatitis C: Recent trends in electrochemical immunosensor and genosensor analysis. Uliana CV, Riccardi CS, Yamanaka H. World J Gastroenterol. 2014 Nov 14;20(42):15476-15491.

Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone. Garimella T1, Wang R1, Luo WL1, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19628. doi: 10.7448/IAS.17.4.19628. eCollection 2014.

Transfusion-transmissible infections among U.S. military recipients of emergently transfused blood products, June 2006-December 2012. Ballard T, Rohrbeck P, Kania M, Johnson LA. MSMR. 2014 Nov;21(11):2-6.

Hepatitis A and B Immunity and Vaccination in Chronic Hepatitis B and C Patients in a Large United States Cohort. Henkle E, Lu M, Rupp LB, Boscarino JA, et al. Clin Infect Dis. 2014 Nov 3. pii: ciu879. [Epub ahead of print]

Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy. Westergaard RP1, Stockman LJ2, Hyland HA3, et al. J Prim Care

Enhanced surveillance of hepatitis C in the EU, 2006 – 2012. Duffell EF1, van de Laar MJ, Amato-Gauci AJ. J Viral Hepat. 2014 Nov 25. doi: 10.1111/jvh.12367. [Epub ahead of print]

The NOTCH pathway is recurrently mutated in diffuse large B cell lymphoma associated with hepatitis C virus infection. Arcaini L1, Rossi D2, Lucioni M3, et al. Haematologica. 2014 Nov 7. pii: haematol.2014.116855.

Clinical value and safety of liver biopsies in patients transplanted for hepatitis C virus-related end-stage liver disease. Brauner C1, Lankisch TO, Fytili P, et al. Transpl Infect Dis. 2014 Nov 13. doi: 10.1111/tid.12310. [Epub ahead of print]

Fibromyalgia Symptoms and Cirrhosis. Rogal SS1, Bielefeldt K, Wasan AD, Szigethy E, Lotrich F, DiMartini AF. Dig Dis Sci. 2014 Nov 30. [Epub ahead of print]

LIVER CANCER

Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. El-Garem H, Ammer A, Shehab H, et al.

Hepatitis C Virus-Associated Cancer. Lin MV1, King LY, Chung RT. Annu Rev Pathol. 2014 Nov 5. [Epub ahead of print]

Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort. Sinn DH1, Gwak GY1, Cho J2, Paik SW1, Yoo BC1. PLoS One. 2014 Nov 5;9(11):e112184. doi: 10.1371/journal.pone.0112184. eCollection 2014.

Metformin does not improve survival in patients with hepatocellular carcinoma. Bhat M, Chaiteerakij R, Harmsen WS, et al. World J Gastroenterol. 2014 Nov 14;20(42):15750-5. doi: 10.3748/wjg.v20.i42.15750.

Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma. Oksuz Z1, Serin MS, Kaplan E, et al. Mol Biol Rep. 2014 Nov 13. [Epub ahead of print]

Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma. Murata M, Yoshida K, Yamaguchi T, Matsuzaki K. World J Gastroenterol. 2014 Nov 7;20(41):15018-15027.

Safety of hepatectomy for elderly patients with hepatocellular carcinoma. Oishi K, Itamoto T, Kohashi T, Matsugu Y, Nakahara H, Kitamoto M. World J Gastroenterol. 2014 Nov 7;20(41):15028-15036.

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)